



Cyprus

Mrs Xenia Ashikales, Ministry of Health

Dr Athos Tsinontides, Health Insurance Organisation

Pricing

- **Price policies for pharmaceuticals**
Statutory pricing for all pharmaceuticals with a marketing authorization license that are available in the private sector – External price referencing is used for imported pharmaceuticals and cost-plus for locally produced pharmaceuticals. – *Public procurement* through tenders for all pharmaceuticals available in government pharmacies.
- **Wholesale Mark-ups**
No wholesale mark-ups. The pricing method in use sets the wholesale price. The wholesalers are free to negotiate their profit with the manufacturers.
- **Pharmacy Mark-ups**
Up to 38% pharmacy mark-up profit margin on all pharmaceuticals available in the private sector. Set by Ministerial Decree.
- **VAT**
No VAT on pharmaceuticals. Diagnostic agents which carry a 15% VAT.
- **Reforms**
Introduction of external price referencing for all imported pharmaceuticals in 2005. New pricing policy is expected with the introduction of the General Healthcare Scheme.

Reimbursement

- **Positive/Negative list**
Positive List (List of Approved Medicines) applicable to eligible patients of the public sector. No list for the private sector.
- **Reference Price System**
Currently no reference price system is in place for reimbursement.
- **Co-payment**
There is 0% or 50% co-payment in the public sector based on the eligibility status of the patient on the pharmaceuticals included in the List of Approved Medicines. Out-of-pocket spending in the private sector.
- **Mechanisms for vulnerable groups**
Vulnerable groups are eligible for 100% reimbursement of the pharmaceuticals included in the List of Approved Medicines in the public sector.
- **Reforms**
New reimbursement policies will be introduced with the implementation of the General Healthcare Scheme.

